Work

Assessing—and Extending—California’s Insulin Manufacturing Initiative

Year: 2023

Type: article

Abstract: This Viewpoint reviews California’s recently proposed CalRx initiative to manufacture biosimilar insulin, highlights challenges facing the initiative, and suggests ways in which, if successful, the initiative could serve as a model for state-managed development of drugs other than insulin, reduce drug prices, and provide other benefits.

Source: JAMA

DOI: 10.1001/jama.2023.0013

Authors: Jacob S. Sherkow, Eli Y. Adashi, I. Glenn Cohen

Institutions: University of Illinois Urbana-Champaign, Brown University, Harvard University

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4317433486